通过选择性KIF18A抑制剂向染色体不稳定的瘤
Aaron F Phillips1, Rumin Zhang1, Mia Jaffe1
1Volastra Therapeutics, New York, NY, USA.
Nature communications
|January 2, 2025
概括
研究人员确定了Kinesin Family Member 18A (KIF18A) 是染色体不稳定的癌症的一个关键漏洞. 用药物VLS-1272抑制KIF18A显示出治疗这些癌症的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 染色体不稳定是一种常见的癌症特征,但在治疗上仍未得到充分利用.
- 鉴定染色体不稳定 (CIN) 癌细胞中的特定脆弱性对于向治疗至关重要.
研究的目的:
- 为了识别对CIN癌细胞生存至关重要的独特基因.
- 开发和验证针对CIN癌症的有针对性的治疗策略.
主要方法:
- 利用癌症依赖地图,发现高复制数异常瘤细胞中必不可少的基因.
- 通过基因淘汰实验验验证了基因素家族成员18A (KIF18A) 作为目标.
- 选化学库以识别和优化KIF18A抑制剂,导致VLS-1272.2.
- 评估了VLS-1272在癌细胞系和瘤外移植中的疗效.
主要成果:
- 鉴定出KIF18A对CIN癌细胞至关重要,其降低会导致线粒体缺陷和瘤生长减少.
- 开发了VLS-1272,一种口服生物可用,强效和选择性的KIF18A抑制剂.
- VLS-1272治疗诱导了染色体凝聚缺陷,线粒停滞和细胞死亡.
- VLS-1272 证明了针对 CIN 癌细胞的特定疗效,并显著抑制了瘤异种移植的生长.
结论:
- 在染色体不稳定的癌症中,KIF18A是一种经过验证的治疗脆弱性.
- VLS-1272是一种有前途的KIF18A抑制剂,具有临床开发潜力.
- 准KIF18A为具有高染色体不稳定性特征的癌症提供了一种新的治疗方法.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.7K
Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
M-Cdk Drives Transition Into Mitosis
5.4K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


